Word: viewed
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
...hope that historians will view the Senate vote on CTBT not as marking the death of arms control but rather as a wake-up call--which spurred responsible leaders from both parties to come together and ensure the U.S.'s continued leadership in building a safer, stabler, freer world...
Gates: In terms of discussing the details of a settlement, I can't do that. Our behavior has been totally fair. We're quite confident that the legal process will uphold our view...
...this struggle for the soul of American art is mapped in all its fitful chaos in the Whitney Museum's mammoth, frenetic show, "The American Century: Art and Culture 1950-2000," part two of a yearlong survey, on view through Feb. 13. The first installment of the retrospective, covering 1900 to 1950, was all about American artists striving to find their identity in the shadow of European masters--and finally making the leap with the figure-breaking canvases of Pollock. The sequel shows the rampantly imaginative shattering of that identity from Pollock onward, shuttling at high speed between the spiritually...
Hundreds of works are on view, all of the Whitney's rooms and corridors crammed with pieces dating from AbEx to those practically yanked off the walls of today's downtown galleries. Yet nowhere is the primal battle pitted so bluntly as in the opening salvos on the top two floors of the show. First is Pollock's Number 27 (1950), its swooping marks scraping away the recognizable shapes of the world, implying in the skeins of paint a web of pure energy, limitless and deep. Its yellows and pinks, its muted greens and blacks are autumnal; a pure buzz...
Schering-Plough's effort may be dead for this year. At a Judiciary Committee panel meeting last week, held out of view in a Capitol hideaway, Senator Patrick Leahy objected to moving the bill. Knight says he is closing down his firm to spend more time on the Gore campaign. But Schering-Plough is expected to continue the battle next year. If it loses again, the company has that contingency covered too: the FDA is currently considering its new super-Claritin for market approval. Its patent wouldn't expire until...